Acute and long-term psychiatric side effects of mefloquine: A follow-up on Danish adverse event reports
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Acute and long-term psychiatric side effects of mefloquine : A follow-up on Danish adverse event reports. / Ringqvist, Åsa; Bech, Per; Glenthøj, Birte; Petersen, Eskild.
I: Travel Medicine and Infectious Disease, Bind 13, Nr. 1, 2015, s. 80-88.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Acute and long-term psychiatric side effects of mefloquine
T2 - A follow-up on Danish adverse event reports
AU - Ringqvist, Åsa
AU - Bech, Per
AU - Glenthøj, Birte
AU - Petersen, Eskild
N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.
PY - 2015
Y1 - 2015
N2 - BACKGROUND: The aim of the study was to explore the profile of acute and long-term psychiatric side effects associated with mefloquine.METHODS: Subjects (n = 73) reported to a Danish national register during five consecutive years for mefloquine associated side effects were included. Acute psychiatric side effects were retrospectively assessed using the SCL-90-R and questions based on Present State Examination (PSE). Subjects reporting suspected psychotic states were contacted for a personal PSE interview. Electronic records of psychiatric hospitalizations and diagnoses were cross-checked. Long-term effects were evaluated with SF-36. SCL-90-R and SF-36 data were compared to age- and gender matched controls.RESULTS: In the SCL-90-R, clinically significant scores for anxiety, phobic anxiety and depression were found in 55%, 51%, and 44% of the mefloquine group. Substantial acute phase psychotic symptoms were found in 15% and were time-limited. Illusions/hallucinations were more frequently observed among women. Cases of hypomania/mania in the acute phase were 5.5%. Significant long-term mental health effects were demonstrated for the SF-36 subscales mental health (MH), role emotional (RE), and vitality (VT) in the mefloquine group compared to matched controls.CONCLUSION: The most frequent acute psychiatric problems were anxiety, depression, and psychotic symptoms. Data indicated that subjects experiencing acute mefloquine adverse side effects may develop long-term mental health problems with a decreased sense of global quality of life with lack of energy, nervousness, and depression.
AB - BACKGROUND: The aim of the study was to explore the profile of acute and long-term psychiatric side effects associated with mefloquine.METHODS: Subjects (n = 73) reported to a Danish national register during five consecutive years for mefloquine associated side effects were included. Acute psychiatric side effects were retrospectively assessed using the SCL-90-R and questions based on Present State Examination (PSE). Subjects reporting suspected psychotic states were contacted for a personal PSE interview. Electronic records of psychiatric hospitalizations and diagnoses were cross-checked. Long-term effects were evaluated with SF-36. SCL-90-R and SF-36 data were compared to age- and gender matched controls.RESULTS: In the SCL-90-R, clinically significant scores for anxiety, phobic anxiety and depression were found in 55%, 51%, and 44% of the mefloquine group. Substantial acute phase psychotic symptoms were found in 15% and were time-limited. Illusions/hallucinations were more frequently observed among women. Cases of hypomania/mania in the acute phase were 5.5%. Significant long-term mental health effects were demonstrated for the SF-36 subscales mental health (MH), role emotional (RE), and vitality (VT) in the mefloquine group compared to matched controls.CONCLUSION: The most frequent acute psychiatric problems were anxiety, depression, and psychotic symptoms. Data indicated that subjects experiencing acute mefloquine adverse side effects may develop long-term mental health problems with a decreased sense of global quality of life with lack of energy, nervousness, and depression.
U2 - 10.1016/j.tmaid.2014.10.021
DO - 10.1016/j.tmaid.2014.10.021
M3 - Journal article
C2 - 25435322
VL - 13
SP - 80
EP - 88
JO - Travel Medicine and Infectious Disease
JF - Travel Medicine and Infectious Disease
SN - 1477-8939
IS - 1
ER -
ID: 137367213